A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer.
Georg A. Bjarnason(Sunnybrook Health Science Centre), J. A. Miller(Ozmosis Research (Canada)), Sebastién J. Hotte(Juravinski Cancer Centre), Denis Soulières(Centre Hospitalier de l’Université de Montréal), Jennifer J. Knox(National Cancer Center), Paweł Zalewski(Medical University of Warsaw), Christian Kollmannsberger(BC Cancer Agency), Mary J. MacKenzie(Cancer Care Ontario), Robyn Jane Macfarlane(Queen Elizabeth II Health Sciences Centre), M. Neil Reaume(The University of Melbourne), Daniel Yick Chin Heng(University of Calgary), Naveen S. Basappa
Cited by 5
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma
|Journal of Clinical Oncology|2013|841
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
|Clinical Cancer Research|2017|635